Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Faderl

Showing results (1-10 of 36) with videos related to

Pageof 4
Sort By:
Hematology/Oncology Clinics of North America|January 9, 2001
Insights into the biologic and molecular abnormalities in adult acute lymphocytic leukemiaS Faderl, M Albitar
Leukemia & Lymphoma|June 28, 2001
The clinical significance of caspase regulation in acute leukemiaS Faderl, Z Estrov
Cytokines, Cellular & Molecular Therapy|July 29, 1998
Residual disease in acute lymphoblastic leukemia of childhood: methods of detection and clinical relevanceS Faderl, Z Estrov
Archives of Pathology & Laboratory Medicine|October 28, 1999
Minimal residual disease in hematologic disordersS Faderl, R Kurzrock, Z Estrov
Current Cancer Drug Targets|December 16, 2006
The JAK-STAT pathway: a therapeutic target in hematological malignanciesA Ferrajoli, S Faderl, F Ravandi, et al.
Leukemia|November 7, 2008
Treatment of B-cell chronic lymphocytic leukemia with nonchemotherapeutic agents: experience with single-agent and combination therapyS Faderl, A Ferrajoli, O Frankfurt, et al.
Annals of Internal Medicine|July 31, 1999
Chronic myelogenous leukemia: biology and therapyS Faderl, M Talpaz, Z Estrov, et al.
Seminars in Oncology|October 26, 2000
New treatment approaches for chronic myelogenous leukemiaS Faderl, H M Kantarjian, M Talpaz, et al.
International Journal of Oncology|November 18, 2000
Clinical significance of minimal residual disease in leukemiaS Faderl, H M Kantarjian, M Talpaz, et al.
Journal of Clinical Pharmacy and Therapeutics|August 3, 2006
Chronic myelomonocytic leukaemia after platinum-based therapy for non-small cell lung cancer: case report and review of the literatureK B Kim, S Faderl, C S Hwang, et al.
Pageof 4

Showing results (1-10 of 36) with videos related to

Sort By:
Pageof 4
Hematology/Oncology Clinics of North America|January 9, 2001
Insights into the biologic and molecular abnormalities in adult acute lymphocytic leukemiaS Faderl, M Albitar
Leukemia & Lymphoma|June 28, 2001
The clinical significance of caspase regulation in acute leukemiaS Faderl, Z Estrov
Cytokines, Cellular & Molecular Therapy|July 29, 1998
Residual disease in acute lymphoblastic leukemia of childhood: methods of detection and clinical relevanceS Faderl, Z Estrov
Archives of Pathology & Laboratory Medicine|October 28, 1999
Minimal residual disease in hematologic disordersS Faderl, R Kurzrock, Z Estrov
Current Cancer Drug Targets|December 16, 2006
The JAK-STAT pathway: a therapeutic target in hematological malignanciesA Ferrajoli, S Faderl, F Ravandi, et al.
Leukemia|November 7, 2008
Treatment of B-cell chronic lymphocytic leukemia with nonchemotherapeutic agents: experience with single-agent and combination therapyS Faderl, A Ferrajoli, O Frankfurt, et al.
Annals of Internal Medicine|July 31, 1999
Chronic myelogenous leukemia: biology and therapyS Faderl, M Talpaz, Z Estrov, et al.
Seminars in Oncology|October 26, 2000
New treatment approaches for chronic myelogenous leukemiaS Faderl, H M Kantarjian, M Talpaz, et al.
International Journal of Oncology|November 18, 2000
Clinical significance of minimal residual disease in leukemiaS Faderl, H M Kantarjian, M Talpaz, et al.
Journal of Clinical Pharmacy and Therapeutics|August 3, 2006
Chronic myelomonocytic leukaemia after platinum-based therapy for non-small cell lung cancer: case report and review of the literatureK B Kim, S Faderl, C S Hwang, et al.
Pageof 4